TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58
2 MARKET SEGMENTATION 61
2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80
5 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81
6 INDUSTRY INSIGHTS 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
7.1.3 INCREASING CASES OF LIVER CANCER 92
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99
8 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100
8.1 OVERVIEW 101
8.2 IMAGING TEST 104
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
8.2.1.1 MR ANGIOGRAPHY (MRA) 105
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
8.2.2 COMPUTED TOMOGRAPHY 106
8.2.3 POSITRON EMISSION TOMOGRAPHY 106
8.2.4 ULTRASOUND 106
8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
8.4.2 CORE NEEDLE BIOPSY 108
8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109
9 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110
9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118
10 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
10.2.1 HEMANGIOMA 124
10.2.2 HEPATIC ADENOMA 124
10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
10.3.4 HEPATOBLASTOMA 126
11 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127
11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
11.2.1 NEXT GENERATION SEQUENCING 132
11.2.2 MICROARRAYS 132
11.2.3 PCR 132
11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
11.3.1 IMAGING 133
11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
11.4.1 ELISA TEST KITS 135
11.4.2 CASSETTE TEST KITS 135
11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135
12 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136
12.1 OVERVIEW 137
12.2 SCREENING 140
12.2.1 PLATFORM BASED PRODUCTS 141
12.2.2 INSTRUMENT BASED PRODUCTS 141
12.2.3 KITS AND REAGENTS 141
12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
12.3.1 PLATFORM BASED PRODUCTS 142
12.3.2 INSTRUMENT BASED PRODUCTS 142
12.3.3 KITS AND REAGENTS 142
12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
12.4.1 PLATFORM BASED PRODUCTS 144
12.4.2 INSTRUMENT BASED PRODUCTS 144
12.4.3 KITS AND REAGENTS 144
12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
12.5.1 PLATFORM BASED PRODUCTS 146
12.5.2 INSTRUMENT BASED PRODUCTS 146
12.5.3 KITS AND REAGENTS 146
12.5.4 OTHER CONSUMABLES 146
13 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147
13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156
14 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157
14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162
15 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163
15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172
16 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173
16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179
17 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180
17.1 ASIA-PACIFIC 181
17.1.1 CHINA 192
17.1.2 INDIA 198
17.1.3 JAPAN 204
17.1.4 INDONESIA 210
17.1.5 PHILIPPINES 216
17.1.6 THAILAND 222
17.1.7 AUSTRALIA 228
17.1.8 MALAYSIA 234
17.1.9 SOUTH KOREA 240
17.1.10 SINGAPORE 246
17.1.11 VIETNAM 252
17.1.12 REST OF ASIA-PACIFIC 258
18 ASIA PACIFIC LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 259
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 259
19 SWOT ANALYSIS 260
20 COMPANY PROFILE 261
20.1 F. HOFFMANN-LA ROCHE LTD. 261
20.1.1 COMPANY SNAPSHOT 261
20.1.2 REVENUE ANALYSIS 261
20.1.3 COMPANY SHARE ANALYSIS 262
20.1.4 PRODUCT PORTFOLIO 262
20.1.5 RECENT DEVELOPMENT 262
20.2 KONINLIJKE PHILIPS N.V. 263
20.2.1 COMPANY SNAPSHOT 263
20.2.2 REVENUE ANALYSIS 263
20.2.3 COMPANY SHARE ANALYSIS 264
20.2.4 PRODUCT PORTFOLIO 264
20.2.5 RECENT DEVELOPMENT 264
20.3 THERMO FISHER SCIENTIFIC INC. 265
20.3.1 COMPANY SNAPSHOT 265
20.3.2 REVENUE ANALYSIS 265
20.3.3 COMPANY SHARE ANALYSIS 266
20.3.4 PRODUCT PORTFOLIO 266
20.3.5 RECENT DEVELOPMENT 266
20.4 BD 267
20.4.1 COMPANY SNAPSHOT 267
20.4.2 REVENUE ANALYSIS 267
20.4.3 COMPANY SHARE ANALYSIS 268
20.4.4 PRODUCT PORTFOLIO 268
20.4.5 RECENT DEVELOPMENTS 269
20.5 SIEMENS HEALTHCARE GMBH 270
20.5.1 COMPANY SNAPSHOT 270
20.5.2 REVENUE ANALYSIS 270
20.5.3 COMPANY SHARE ANALYSIS 271
20.5.4 PRODUCT PORTFOLIO 271
20.5.5 RECENT DEVELOPMENT 271
20.6 AGILENT TECHNOLOGIES, INC. 272
20.6.1 COMPANY SNAPSHOT 272
20.6.2 REVENUE ANALYSIS 272
20.6.3 PRODUCT PORTFOLIO 273
20.6.4 RECENT DEVELOPMENTS 273
20.7 ABK BIOMEDICAL INC. 274
20.7.1 COMPANY SNAPSHOT 274
20.7.2 PRODUCT PORTFOLIO 274
20.7.3 RECENT DEVELOPMENT 274
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 275
20.8.1 COMPANY SNAPSHOT 275
20.8.2 REVENUE ANALYSIS 275
20.8.3 PRODUCT PORTFOLIO 276
20.8.4 RECENT DEVELOPMENT 276
20.9 ALTOGEN BIOSYSTEMS 277
20.9.1 COMPANY SNAPSHOT 277
20.9.2 PRODUCT PORTFOLIO 277
20.9.3 RECENT DEVELOPMENT 277
20.10 BIOCEPT, INC. 278
20.10.1 COMPANY SNAPSHOT 278
20.10.2 REVENUE ANALYSIS 278
20.10.3 PRODUCT PORTFOLIO 279
20.10.4 RECENT DEVELOPMENT 279
20.11 BODITECH MED INC. 280
20.11.1 COMPANY SNAPSHOT 280
20.11.2 PRODUCT PORTFOLIO 280
20.11.3 RECENT DEVELOPMENTS 280
20.12 DIAGNOSTIC BIOSYSTEMS INC. 281
20.12.1 COMPANY SNAPSHOT 281
20.12.2 PRODUCT PORTFOLIO 281
20.12.3 RECENT DEVELOPMENT 281
20.13 DIAZYME LABORATORIES, INC. 282
20.13.1 COMPANY SNAPSHOT 282
20.13.2 PRODUCT PORTFOLIO 282
20.13.3 RECENT DEVELOPMENT 282
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 283
20.14.1 COMPANY SNAPSHOT 283
20.14.2 PRODUCT PORTFOLIO 283
20.14.3 RECENT DEVELOPMENT 283
20.15 EPIGENOMICS AG 284
20.15.1 COMPANY SNAPSHOT 284
20.15.2 REVENUE ANALYSIS 284
20.15.3 PRODUCT PORTFOLIO 285
20.15.4 RECENT DEVELOPMENT 285
20.16 FUJIFILM CORPORATION 286
20.16.1 COMPANY SNAPSHOT 286
20.16.2 REVENUE ANALYSIS 286
20.16.3 PRODUCT PORTFOLIO 287
20.16.4 RECENT DEVELOPMENT 287
20.17 FUJIREBIO 288
20.17.1 COMPANY SNAPSHOT 288
20.17.2 PRODUCT PORTFOLIO 288
20.17.3 RECENT DEVELOPMENTS 288
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 289
20.18.1 COMPANY SNAPSHOT 289
20.18.2 PRODUCT PORTFOLIO 289
20.18.3 RECENT DEVELOPMENT 289
20.19 ILLUMINA, INC. 290
20.19.1 COMPANY SNAPSHOT 290
20.19.2 REVENUE ANALYSIS 290
20.19.3 PRODUCT PORTFOLIO 291
20.19.4 RECENT DEVELOPMENTS 292
20.20 MOLGEN 293
20.20.1 COMPANY SNAPSHOT 293
20.20.2 PRODUCT PORTFOLIO 293
20.20.3 RECENT DEVELOPMENT 293

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.